Fig. 2

The role of Src in the FGF19-FGFR4 axis in HCC. a, b The mRNA expression levels of FGF19 and FGFR4 in the PLC5 cell line. The PLC5 cell line expresses FGFR4, but not FGF19. HUH7 was used as a reference sample. c, d Western blot analysis of the FGF19-FGFR4-Src axis after treating PLC5 and HUH7 cells with the Src inhibitor, saracatinib and recombinant FGF19. Saracatinib treatment decreased the phosphorylation of STAT3 and the expression of FGFR4. e Western blot analysis after silencing FGF19 in the three HCC cell lines. The silencing of FGF19 decreased FGFR4 phosphorylation. f, g Immunofluorescence staining of pSrc (red) and pSTAT3 (green) in SNU878 cells treated with either FGF19 siRNA or control siRNA. FGF19 silencing suppressed pSTAT3, but pSrc was not affected